ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 256 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q4 2020. The put-call ratio across all filers is 0.26 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,496,678 | -31.6% | 182,235 | -11.5% | 0.03% | -27.7% |
| Q2 2023 | $9,504,210 | +14.0% | 206,031 | -0.9% | 0.05% | +4.4% |
| Q1 2023 | $8,335,106 | -21.8% | 207,858 | -9.7% | 0.04% | -26.2% |
| Q4 2022 | $10,664,888 | +36.7% | 230,194 | +22.2% | 0.06% | +19.6% |
| Q3 2022 | $7,803,000 | +301.4% | 188,421 | +478.3% | 0.05% | +325.0% |
| Q2 2022 | $1,944,000 | +764.0% | 32,581 | +1282.3% | 0.01% | +1100.0% |
| Q2 2021 | $225,000 | -87.2% | 2,357 | -84.8% | 0.00% | -90.0% |
| Q1 2021 | $1,761,000 | +383.8% | 15,466 | +489.0% | 0.01% | +400.0% |
| Q4 2020 | $364,000 | -6.4% | 2,626 | -30.9% | 0.00% | -50.0% |
| Q2 2015 | $389,000 | +18.2% | 3,800 | -28.3% | 0.00% | +33.3% |
| Q1 2015 | $329,000 | – | 5,300 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 727,426 | $25,932,737 | 4.72% |
| RTW INVESTMENTS, LP | 5,405,089 | $192,691,423 | 4.07% |
| First Light Asset Management, LLC | 1,125,032 | $40,107,391 | 3.81% |
| CHI Advisors LLC | 215,000 | $7,664,750 | 3.04% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 250,052 | $8,914,354 | 3.00% |
| SPHERA FUNDS MANAGEMENT LTD. | 259,135 | $9,238,163 | 1.68% |
| Rock Springs Capital Management LP | 1,476,441 | $52,635,122 | 1.41% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 679,459 | $24,222,713 | 1.31% |
| Privium Fund Management B.V. | 115,241 | $4,108,341 | 1.22% |
| SECTOR GAMMA AS | 115,166 | $4,105,668 | 1.05% |